IDEAYA Biosciences Inc - IDYA Income before deduction of interest, taxes and amortization

The EBITDA history of IDEAYA Biosciences (IDYA) demonstrates the dynamics of commercial revenues, where the value of 0.00 reflects the metric's balance. IDEAYA Biosciences (IDYA) is vulnerable to logistic disruptions in the supply of rare reagents and sanction restrictions. Leadership in synthetic lethality and alliances with tech giants accelerate drug launches, yet a narrow specialization in early-stage therapies creates significant binary risks for capital.

IDEAYA Bio - IDYA Operating profit EBITDA (period 11/23/2025 - 11/10/2026)

IDEAYA Biosciences, Inc. (IDYA) - metric breakdowns and financial figures

- market value and analyst target forecast:

Market Price IDEAYA Corp|IDYA - Consensus Target

- issuer market value details:

Market Value IDEAYA Biosciences|IDYA - Real Price to Acquire Entire Company

- book capitalization information:

Book Price of a Share IDEAYA Biosciences|IDYA - Book Capitalization|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Aggregate Company Assets

- company total debt and liquidity indicators:

All Debt to Shareholders' Equity Ratio IDEAYA Biosciences|IDYA - Long-Term Debt to Capital|Short-Term Indebtedness to Equity IDEAYA Biosciences Inc|IDYA - Company Aggregate Debts|Debts to Book Value IDEAYA Biosciences|IDYA - Company Long-Term Liabilities|Amount of Current Liabilities IDEAYA Biosciences|Immediate Liquidity ideayabio.com

- financial results and valuation multiples details:

IDYA - Net Profit|Net Profit Forecast IDEAYA Biosciences|IDYA - Price to Earnings Ratio|Future Price to Earnings Multiple ideayabio.com|IDYA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio IDEAYA Biosciences|IDYA - Operating profit EBITDA|Earnings per share for the trailing year IDEAYA Biosciences|IDYA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ideayabio.com|IDYA - Earnings per share growth in current year|Expected earnings per share trend next year IDEAYA Biosciences

Summary company analytics:IDEAYA Biosciences

This indicator tracks daily cash flow from operating activities, allowing for an assessment of real operational efficiency and the capital burn rate. By analyzing the total EBITDA for the period on the GURU.Markets platform, an investor determines the funding sustainability for scaling the oncology portfolio clinical trials of IDEAYA Biosciences (IDYA), which is supported by strategic partnerships with global biopharmaceutical behemoths.

Competitor analysis for IDEAYA Biosciences